JP3998282B2 - A new saponin glycoside derived from Ginseng - Google Patents
A new saponin glycoside derived from Ginseng Download PDFInfo
- Publication number
- JP3998282B2 JP3998282B2 JP23904796A JP23904796A JP3998282B2 JP 3998282 B2 JP3998282 B2 JP 3998282B2 JP 23904796 A JP23904796 A JP 23904796A JP 23904796 A JP23904796 A JP 23904796A JP 3998282 B2 JP3998282 B2 JP 3998282B2
- Authority
- JP
- Japan
- Prior art keywords
- ginseng
- methanol
- glu
- saponin glycoside
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【０００１】
【発明の属する技術分野】
本発明は三七人参由来の新規サポニン配糖体に関する。
【０００２】
【従来の技術】
三七人参は、ウコギ科（Araliaceae）のサンシチニンジン ［Panax notoginseng（Burk.）F.H.Chen （= P. sanchi Hoo, P. pseudo-ginseng Wall. var. notoginseng（Burk.）Hoo et Tseng）］ の根を乾燥したものであり、現在市場では「三七」「人参三七」「参三七」「田三七」「田七」「田七人参」などと称し、また別名を「山漆」「金不換」という。
本植物は中国雲南省東南部から広西省西南部の極限された地域に分布するもので、既に清代頃から同地域で栽培化されており、１６世紀末頃から中国南部地方で民間的に金瘡、打撲、挫傷などの血症に対し、止血、消炎、鎮痛などの薬として用いられている。
【０００３】
現代においてもこれら止血、消炎（消腫）、鎮痛作用を主体に、内服、外用を問わず、臨床的に優秀な効果が認められている。漢方でいう止血の概念は非常に広範なものであり、補血作用やお血（ふる血）を化して水にすることにより痛みを止めるなどの作用も包含している。
すなわち、打身、ねんざ、腫痛出血、吐血、鼻血、婦人の崩漏、産後のお阻腹痛など諸出血症状に応用する。その他、近年では強心作用が見出され、冠状動脈疾患、狭心症、心筋梗塞、高血圧、コレステロール過多症等にも応用されるようになってきている。また現代中国では、慢性肝炎、急性肝炎等の肝疾患にも用いられており、今後、抗炎症剤としての使用も期待される。
【０００４】
【発明が解決しようとする課題】
三七人参の成分としては、サポニン配糖体であるジンセノサイド（ginsenoside）Rb1, Rg1, Rg2, Ra, Rb2, Rd, Re, Roの他、パナキシノール（panaxynol）、β−シロステロール（β−sitosterol）が知られているが、これらの成分はすべて人参（オタネニンジン＝Panax ginseng C.A.Meyer）と共通するものであって、三七人参特有の成分については精査されておらず、三七人参の薬理作用を説明するには不十分であるといえる。
そこで本発明者らは、三七人参の活性本体であると推測される三七人参特有の成分について精査し、新規化合物３種を単離し、構造決定するに至った。
【０００５】
【課題を解決するための手段】
本発明は次の式で表される三七人参由来のサポニン配糖体を提供するものである。
【化３】
【化４】
【０００６】
【発明の実施の形態】
本発明の新規なサポニン配糖体は、三七人参より下記の抽出操作によって抽出、単離される。
三七人参をメタノールで熱時抽出し、そのメタノール抽出エキスを酢酸エチルと水で液−液分配し、水相移行部にｎ−ブタノールを加えて再度液−液分配し、そのブタノール相について順相シリカゲルカラムクロマトグラフィ［クロロホルム：メタノール：水（５０：１０：１→７：３：０.５→５：５：１）で順次溶出］に付し、薄層クロマトグラフィで確認しながら、順に５つの画分に分け、その第４画分を逆相シリカゲルカラムクロマトグラフィ（６０％、７０％、１００％メタノールにて順次溶出）に付し、その６０％メタノール溶出部をさらに逆相高速液体クロマトグラフィ（ＨＰＬＣ）［溶出液：メタノール−水（６５：３５、ｖ／ｖ）、流速：１０.０ｍｌ／分］で分離精製することにより目的とするサポニン配糖体３種（それぞれサンシチサポニンＡ、サンシチサポニンＢ、およびサンシチサポニンＣと命名した）を得る。
【０００７】
上記で得られるサポニン配糖体は表１に示す化学構造を有する。
【表１】
本発明のサポニン配糖体は、これまで三七人参が用いられていた種々の疾患の治療に有用であると考えられ、とくに肝疾患の治療に有用である。
【０００９】
【実施例】
つぎに実施例および試験例を挙げて本発明のサポニン配糖体の製法および薬理作用の一例を示す。
実施例１〜３
（１）雲南省生三七（１２ｋｇ）を粉末にし、メタノール（１８リットル）で４回熱時抽出した。メタノール抽出液を合わせて減圧下溶媒を留去し、メタノール抽出エキス（１０５０ｇ、生薬からの収率８.８％）を得た。このメタノール抽出エキス（５１０ｇ）を酢酸エチル−水（１：１）で分配し、酢酸エチル移行部（４３.７ｇ、０.７５％）と水移行部を得、この水移行部にｎ−ブタノールを加えてさらに液−液分配抽出してｎ−ブタノール移行部エキス（４３０ｇ、７.４％）および水移行部エキス（３７.９ｇ、０.６５％）を得た。
ｎ−ブタノール移行部エキス（１００ｇ）を順相カラムクロマトグラフィ［３ｋｇ、クロロホルム：メタノール：水（５０：１０：１→７：３：０.５→５：５：１）で順次溶出］に付しＴＬＣで確認しながら順に、画分１（１４.８ｇ、０.９１％）、画分２（２.３ｇ、０.１４％）、画分３（４.０ｇ、０.２５％）、画分４（２７.８ｇ、１.７２％）、画分５（９.４ｇ、０.５８％）を得た。
【００１０】
上記画分４を逆相シリカゲルカラムクロマトグラフィ（１ｋｇ、６０％、７０％、１００％メタノールで順次溶出）に付し、その６０％メタノール溶出部（１.１ｇ）をさらに逆相ＨＰＬＣ［カラム：ＹＭＣ−Pack R & D ODS-5(250 × 20 mm i. d）、溶出液；メタノール−水（６５：３５、ｖ／ｖ）、流速；１０.０ｍｌ／分］で分離精製することによりサンシチサポニンＡ（８５.３ｍｇ、０.００６％）、サンシチサポニンＢ（５５.８ｍｇ、０.００４％）、およびサンシチサポニンＣ（７３.３ｍｇ、０.００５％）を得た。これらの物質は下記の物性を示す。
【００１１】
サンシチサポニンＡの物性
分子式：C54H92O24
融点：１９７〜２００℃
比旋光度(C=0.003, MeOH)：[α]24 D=+18.9°
マススペクトル(FAB-MS)m/z：1169(M+2Na-H)+, 1147(M+Na)+, 1129(M+Na-H2O)+(100%)
マススペクトル(HR-FAB-MS)m/z：C54H92O24Na, 計算値：1147.5876；実測値：1147.5895
赤外線吸収スペクトル(IR, ν max cm-1, KBr)：3432, 1632, 1072
13C NMR (125 Mz、ピリジン-d5、δ ppm）：142.3(d), 122.7(d), 106.0(d), 105.1(d), 104.8(d), 98.1(d), 89.0(d), 83.3(s), 83.3(d), 78.7(d), 78.3(d)x4, 78.1(d), 77.9(d),77.1(d)x2, 75.2(d), 75.0(d), 71.7(d), 71.6(d)x3, 70.5(d), 70.0(s), 70.0(t), 62.8(t)x3, 56.4(d), 52.1(d), 51.4(s), 50.1(d), 49.6(d), 40.1(d), 39.7(t), 39.7(s), 39.2(t), 36.9(s), 35.1(t), 30.8(t), 30.7(q), 30.6(s), 30.6(t), 28.1(q), 26.8(t)x2, 23.3(q), 18.4(t), 17.2(q), 16.6(q), 16.3(q), 16.0(q)
1H NMR (500 Mz, ピリジン-d5, δ ppm)：0.85(3H, s), 0.89(3H, s), 1.03(3H, s), 1.11(3H, s), 1.29(3H, s), 1.55(6H, s), 1.61(3H, s), 4.92(1H, d, J=7.6), 5.10(1H, d,J=7.6), 5.18(1H, d, J=7.6), 5.37(1H, d, J=7.3), 6.08(1H, d, J=15.6), 6.19(1H, m)
【００１２】
サンシチサポニンＢの物性
分子式：C54H90O24
融点：２０１〜２０４℃
比旋光度(C=0.003, MeOH)：[α]23 D=+17.8°
マススペクトル(FAB-MS)m/z：1145(M+Na)+(100%)
マススペクトル(HR-FAB-MS)m/z:C54H90O24Na, 計算値：1145.5720；実測値：1145.5717
赤外線吸収スペクトル(IR, ν max cm-1, KBr)：3410, 1638, 1078
13C NMR (125 Mz, ピリジン-d5, δ ppm)：202.2(s), 144.4(s), 125.6(t), 106.0(d), 105.6(d), 105.1(d), 98.0(d), 89.0(d), 83.5(d), 83.2(s), 79.4(d), 78.5(d)x2, 78.4(d), 78.3(d), 78.1(d), 78.0(d), 77.1(d), 76.7(d), 75.2(d), 74.8(d), 71.8(d), 71.7(d)x2, 71.3(d), 70.3(t), 70.2(d), 62.9(t), 62.8(t), 62.7(t), 56.4(d), 52.1(d), 51.5(s), 50.2(d), 49.5(d), 40.0(s), 39.7(s), 39.2(t), 36.9(s), 35.1(t), 32.8(t), 30.8(t), 30.7(t), 29.8(t), 28.1(q), 26.8(t), 26.7(t), 21.9(q), 18.4(t), 17.8(q), 17.4(q), 16.6(q), 16.3(q), 16.0(q)
1H NMR (500 Mz, ピリジン-d5, δ ppm)：0.82(3H, s), 0.92(3H, s), 0.97(3H, s), 1.11(3H, s), 1.28(3H, s), 1.59(3H, s), 1.83(3H, s), 4.93(1H, d, J=7.6), 5.03(1H, d,J=7.2), 5.11(1H, d, J=7.3), 5.38(1H, d, J=7.6)
【００１３】
サンシチサポニンＣの物性
分子式：C54H92O25
融点：１９９〜２０２℃
比旋光度(C=0.003, MeOH)：[α]22 D=+14.4°
マススペクトル(FAB-MS)m/z：1185(M+2Na-H)+, 1163(M+Na)+, 1145(M+Na-H2O)+(100%)
マススペクトル(HR-FAB-MS)m/z:C54H92O25Na, 計算値：1163.5826；実測値：1163.5873
赤外線吸収スペクトル(IR, ν max cm-1, KBr)：3410, 1638, 1078
13C NMR (125 Mz, ピリジン-d5, δ ppm)：146.0(d), 113.5(d), 106.0(d), 105.2(d), 105.1(d), 98.1(d), 90.0(d), 89.0(s), 83.4(s), 83.3(d), 79.1(d), 78.4(d), 78.3(d)x3, 78.2(d), 78.1(d), 77.1(d), 77.0(d), 75.2(d), 74.8(d), 71.8(d), 71.7(d), 71.6(d), 71.5(d), 70.2(d), 70.0(t), 62.9(t), 62.8(t), 62.7(t), 56.4(d), 51.7(d), 51.4(s), 50.2(d), 49.4(d), 40.0(s), 39.7(s), 39.2(t), 36.9(s), 35.1(t), 32.6(t), 30.9(t), 30.8(t), 28.1(q), 26.8(t), 26.7(t), 26.3(t), 22.6(q), 18.5(t), 17.6(q), 17.4(q), 16.6(q), 16.3(q), 16.0(q)
1H NMR (500 Mz, ピリジン-d5, δ ppm)：0.83(3H, s), 0.94(3H, s), 0.99(3H, s), 1.10(3H, s), 1.28(3H, s), 1.64(3H, s), 1.95(3H, s), 4.79(dd-like), 4.91(1H, d, J=7.3), 5.09(1H, d,-like), 5.10(1H, d-like), 5.36(1H, d, J=7.6)
【００１４】
薬理試験
コンカナバリンＡ誘発肝障害モデル試験
（１）試験方法：
雌性BALB/cマウス（８週令、１群５または６匹）にコンカナバリンＡを１０ｍｇ／ｋｇの用量で尾静脈より投与した。２０時間後に採血し、血清トランスアミラーゼ（ＧＯＴおよびＧＰＴ）を市販キットを用いて測定した。被験薬物はコンカナバリンＡ投与の２時間前に腹腔内投与（i.p.）した。対照群には何らの薬物も投与しなかった。
（２）被験薬物：
前記実施例において得られた、三七人参のメタノール抽出エキスを酢酸エチルと水で液−液分配し、更に水移行部をｎ−ブタノールで液−液分配し、ｎ−ブタノール移行部について、ｎ−ブタノールを留去したエキス部分（サンシチサポニンＡ、ＢおよびＣを含有）を被験薬物とした。
【００１５】
（３）実験結果：
上記実験結果を表２に示す。
【表２】
BACKGROUND OF THE INVENTION
The present invention relates to a novel saponin glycoside derived from Ginseng.
[0002]
[Prior art]
37 Ginseng is the root of Araliaceae, Panax notoginseng (Burk.) FHChen (= P. sanchi Hoo, P. pseudo-ginseng Wall. Var. Notoginseng (Burk.) Hoo et Tseng) In the current market, it is called “37”, “carrot 37,” “sansanchi,” “tasanchi,” “tachichi,” “tabanachi ginseng,” and so on. It's called money exchange.
This plant is distributed in a limited area from southeastern Yunnan to southwestern Guangxi, and has already been cultivated in the same area since the Qing Dynasty. It is used as a medicine for hemostasis, anti-inflammation, analgesia, etc. against blood pressure such as bruise and contusion.
[0003]
Even in modern times, these hemostasis, anti-inflammatory (anti-tumor), and analgesic actions are mainly used, and clinically excellent effects are recognized regardless of internal use or external use. The concept of hemostasis in Kampo is very broad, and includes the effects of supplementing blood and stopping pain by turning the blood into blood.
That is, it is applied to various bleeding symptoms such as bruise, sprains, painful bleeding, vomiting, nosebleed, collapse of a woman, and postpartum sural pain. In addition, a cardiotonic effect has been found in recent years, and it has been applied to coronary artery disease, angina pectoris, myocardial infarction, hypertension, hypercholesterolosis, and the like. In modern China, it is also used for liver diseases such as chronic hepatitis and acute hepatitis, and is expected to be used as an anti-inflammatory agent in the future.
[0004]
[Problems to be solved by the invention]
In addition to ginsenoside Rb1, Rg1, Rg2, Ra, Rb2, Rd, Re, Ro, panaxynol, β-sisterosterol (β-sitosterol) However, all these ingredients are common to ginseng (Panax ginseng CAMeyer), and the ingredients specific to ginseng have not been scrutinized, explaining the pharmacological action of ginseng It's not enough to do that.
Therefore, the present inventors have scrutinized components unique to 37 ginseng, which is presumed to be the active body of 37 ginseng, and have isolated three new compounds to determine the structure.
[0005]
[Means for Solving the Problems]
The present invention provides a saponin glycoside derived from Ginseng represented by the following formula.
[Chemical 3]
[Formula 4]
[0006]
DETAILED DESCRIPTION OF THE INVENTION
The novel saponin glycoside of the present invention is extracted and isolated from the ginseng by the following extraction operation.
37 ginseng was extracted hot with methanol, the methanol extract was liquid-liquid partitioned with ethyl acetate and water, n-butanol was added again to the aqueous phase transition part, and liquid-liquid partition was repeated. Phase silica gel column chromatography [sequential elution with chloroform: methanol: water (50: 10: 1 → 7: 3: 0.5 → 5: 5: 1)] The fourth fraction was subjected to reverse phase silica gel column chromatography (elution with 60%, 70%, and 100% methanol sequentially), and the 60% methanol elution portion was further subjected to reverse phase high performance liquid chromatography (HPLC ) [Eluent: Methanol-water (65:35, v / v), flow rate: 10.0 ml / min] to separate and purify the three saponin glycosides Obtaining Re Panax saponin A, Panax saponin B, and Panax was named saponin C).
[0007]
The saponin glycoside obtained above has the chemical structure shown in Table 1.
[Table 1]
The saponin glycoside of the present invention is considered to be useful for the treatment of various diseases that have been used so far, and is particularly useful for the treatment of liver diseases.
[0009]
【Example】
Next, examples and test examples will be given to show an example of the production method and pharmacological action of the saponin glycoside of the present invention.
Examples 1-3
(1) Yunnan Seizo (12 kg) was powdered and extracted with methanol (18 liters) four times with heat. The methanol extracts were combined, and the solvent was distilled off under reduced pressure to obtain a methanol extract (1050 g, yield 8.8% from crude drug). This methanol extract (510 g) was partitioned with ethyl acetate-water (1: 1) to obtain an ethyl acetate transfer part (43.7 g, 0.75%) and a water transfer part. In this water transfer part, n-butanol was obtained. Was further extracted by liquid-liquid partition extraction to obtain an n-butanol transfer part extract (430 g, 7.4%) and a water transfer part extract (37.9 g, 0.65%).
The n-butanol transfer part extract (100 g) was subjected to normal phase column chromatography [3 kg, eluted sequentially with chloroform: methanol: water (50: 10: 1 → 7: 3: 0.5 → 5: 5: 1)]. While confirming by TLC, fraction 1 (14.8 g, 0.91%), fraction 2 (2.3 g, 0.14%), fraction 3 (4.0 g, 0.25%), fraction Fraction 4 (27.8 g, 1.72%), fraction 5 (9.4 g, 0.58%) were obtained.
[0010]
Fraction 4 was subjected to reverse phase silica gel column chromatography (eluted sequentially with 1 kg, 60%, 70%, and 100% methanol), and the 60% methanol eluate (1.1 g) was further subjected to reverse phase HPLC [column: YMC -Pack R & D ODS-5 (250 × 20 mm id), eluent: methanol-water (65:35, v / v), flow rate: 10.0 ml / min] Saponin A (85.3 mg, 0.006%), Sansitisaponin B (55.8 mg, 0.004%), and Sansitissaponin C (73.3 mg, 0.005%) were obtained. These substances exhibit the following physical properties.
[0011]
Physical properties of Sansitissaponin A: C 54 H 92 O 24
Melting point: 197-200 ° C
Specific rotation (C = 0.003, MeOH): [α] 24 D = + 18.9 °
Mass spectrum (FAB-MS) m / z: 1169 (M + 2Na-H) + , 1147 (M + Na) + , 1129 (M + Na-H 2 O) + (100%)
Mass spectrum (HR-FAB-MS) m / z: C 54 H 92 O 24 Na, calculated value: 1147.5876; measured value: 1147.5895
Infrared absorption spectrum (IR, ν max cm -1 , KBr): 3432, 1632, 1072
13 C NMR (125 Mz, pyridine-d 5 , δ ppm): 142.3 (d), 122.7 (d), 106.0 (d), 105.1 (d), 104.8 (d), 98.1 (d), 89.0 (d) , 83.3 (s), 83.3 (d), 78.7 (d), 78.3 (d) x4, 78.1 (d), 77.9 (d), 77.1 (d) x2, 75.2 (d), 75.0 (d), 71.7 ( d), 71.6 (d) x3, 70.5 (d), 70.0 (s), 70.0 (t), 62.8 (t) x3, 56.4 (d), 52.1 (d), 51.4 (s), 50.1 (d), 49.6 (d), 40.1 (d), 39.7 (t), 39.7 (s), 39.2 (t), 36.9 (s), 35.1 (t), 30.8 (t), 30.7 (q), 30.6 (s), 30.6 (t), 28.1 (q), 26.8 (t) x2, 23.3 (q), 18.4 (t), 17.2 (q), 16.6 (q), 16.3 (q), 16.0 (q)
1 H NMR (500 Mz, pyridine-d 5 , δ ppm): 0.85 (3H, s), 0.89 (3H, s), 1.03 (3H, s), 1.11 (3H, s), 1.29 (3H, s) , 1.55 (6H, s), 1.61 (3H, s), 4.92 (1H, d, J = 7.6), 5.10 (1H, d, J = 7.6), 5.18 (1H, d, J = 7.6), 5.37 ( 1H, d, J = 7.3), 6.08 (1H, d, J = 15.6), 6.19 (1H, m)
[0012]
Physical properties of Sansitissaponin B: C 54 H 90 O 24
Melting point: 201-204 ° C
Specific rotation (C = 0.003, MeOH): [α] 23 D = + 17.8 °
Mass spectrum (FAB-MS) m / z: 1145 (M + Na) + (100%)
Mass spectrum (HR-FAB-MS) m / z: C 54 H 90 O 24 Na, calculated value: 1145.5720; actual value: 1145.5717
Infrared absorption spectrum (IR, ν max cm -1 , KBr): 3410, 1638, 1078
13 C NMR (125 Mz, pyridine-d 5 , δ ppm): 202.2 (s), 144.4 (s), 125.6 (t), 106.0 (d), 105.6 (d), 105.1 (d), 98.0 (d) , 89.0 (d), 83.5 (d), 83.2 (s), 79.4 (d), 78.5 (d) x2, 78.4 (d), 78.3 (d), 78.1 (d), 78.0 (d), 77.1 (d ), 76.7 (d), 75.2 (d), 74.8 (d), 71.8 (d), 71.7 (d) x2, 71.3 (d), 70.3 (t), 70.2 (d), 62.9 (t), 62.8 ( t), 62.7 (t), 56.4 (d), 52.1 (d), 51.5 (s), 50.2 (d), 49.5 (d), 40.0 (s), 39.7 (s), 39.2 (t), 36.9 ( s), 35.1 (t), 32.8 (t), 30.8 (t), 30.7 (t), 29.8 (t), 28.1 (q), 26.8 (t), 26.7 (t), 21.9 (q), 18.4 ( t), 17.8 (q), 17.4 (q), 16.6 (q), 16.3 (q), 16.0 (q)
1 H NMR (500 Mz, pyridine-d 5 , δ ppm): 0.82 (3H, s), 0.92 (3H, s), 0.97 (3H, s), 1.11 (3H, s), 1.28 (3H, s) , 1.59 (3H, s), 1.83 (3H, s), 4.93 (1H, d, J = 7.6), 5.03 (1H, d, J = 7.2), 5.11 (1H, d, J = 7.3), 5.38 ( (1H, d, J = 7.6)
[0013]
Physical properties of Sansitissaponin C: C 54 H 92 O 25
Melting point: 199-202 ° C
Specific rotation (C = 0.003, MeOH): [α] 22 D = + 14.4 °
Mass spectrum (FAB-MS) m / z: 1185 (M + 2Na-H) + , 1163 (M + Na) + , 1145 (M + Na-H 2 O) + (100%)
Mass spectrum (HR-FAB-MS) m / z: C 54 H 92 O 25 Na, calculated value: 1163.5826; actual value: 1163.5873
Infrared absorption spectrum (IR, ν max cm -1 , KBr): 3410, 1638, 1078
13 C NMR (125 Mz, pyridine-d 5 , δ ppm): 146.0 (d), 113.5 (d), 106.0 (d), 105.2 (d), 105.1 (d), 98.1 (d), 90.0 (d) , 89.0 (s), 83.4 (s), 83.3 (d), 79.1 (d), 78.4 (d), 78.3 (d) x3, 78.2 (d), 78.1 (d), 77.1 (d), 77.0 (d ), 75.2 (d), 74.8 (d), 71.8 (d), 71.7 (d), 71.6 (d), 71.5 (d), 70.2 (d), 70.0 (t), 62.9 (t), 62.8 (t ), 62.7 (t), 56.4 (d), 51.7 (d), 51.4 (s), 50.2 (d), 49.4 (d), 40.0 (s), 39.7 (s), 39.2 (t), 36.9 (s ), 35.1 (t), 32.6 (t), 30.9 (t), 30.8 (t), 28.1 (q), 26.8 (t), 26.7 (t), 26.3 (t), 22.6 (q), 18.5 (t ), 17.6 (q), 17.4 (q), 16.6 (q), 16.3 (q), 16.0 (q)
1 H NMR (500 Mz, pyridine-d 5 , δ ppm): 0.83 (3H, s), 0.94 (3H, s), 0.99 (3H, s), 1.10 (3H, s), 1.28 (3H, s) , 1.64 (3H, s), 1.95 (3H, s), 4.79 (dd-like), 4.91 (1H, d, J = 7.3), 5.09 (1H, d, -like), 5.10 (1H, d-like ), 5.36 (1H, d, J = 7.6)
[0014]
Pharmacological test Concanavalin A-induced liver injury model test (1) Test method:
Concanavalin A was administered to female BALB / c mice (8 weeks old, 5 or 6 mice per group) from the tail vein at a dose of 10 mg / kg. Blood was collected 20 hours later, and serum transamylase (GOT and GPT) was measured using a commercially available kit. The test drug was administered intraperitoneally (ip) 2 hours before the administration of concanavalin A. The control group did not receive any drug.
(2) Test drug:
The extract of 37 ginseng methanol obtained in the above example was subjected to liquid-liquid partitioning with ethyl acetate and water, and the water transfer part was subjected to liquid-liquid partition with n-butanol. -The extract part from which butanol was distilled off (containing sansitaponins A, B and C) was used as a test drug.
[0015]
(3) Experimental results:
The experimental results are shown in Table 2.
[Table 2]
Claims (1)
で示される化合物。The following structural formula, which is isolated from Ginseng:
A compound represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23904796A JP3998282B2 (en) | 1996-09-10 | 1996-09-10 | A new saponin glycoside derived from Ginseng |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23904796A JP3998282B2 (en) | 1996-09-10 | 1996-09-10 | A new saponin glycoside derived from Ginseng |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1087691A JPH1087691A (en) | 1998-04-07 |
| JP3998282B2 true JP3998282B2 (en) | 2007-10-24 |
Family
ID=17039090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23904796A Expired - Fee Related JP3998282B2 (en) | 1996-09-10 | 1996-09-10 | A new saponin glycoside derived from Ginseng |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3998282B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100605114B1 (en) * | 2003-09-06 | 2006-07-28 | 주식회사 오스코텍 | Composition comprising Notoginseng Radix extract for preventing and treating of arthritis as an effective component |
| CN102766184B (en) * | 2012-08-01 | 2014-08-13 | 南通大学 | Protopanoxadiol peroxide derivatives as well as preparation method and application thereof |
| KR101621356B1 (en) * | 2014-09-05 | 2016-05-17 | 한국과학기술원 | Use of ginsenoside F2 for prophylaxis and treatment of liver disease |
-
1996
- 1996-09-10 JP JP23904796A patent/JP3998282B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1087691A (en) | 1998-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2515891T3 (en) | Method of Preparation of a Pharmaceutical Composition Containing Ginseng Secondary Glycosides | |
| WO2006034655A1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| Hou | The chemical constituents of ginseng plants | |
| JP6372897B2 (en) | Herbal medicine composition | |
| WO2004054595A1 (en) | A method for preparing low polar ginsenoside and aglucon thereof by catalytic pyrolysis | |
| CN106967147B (en) | C27Spirostan type steroid saponin compounds and its pharmaceutical composition and its application | |
| Ravikumar et al. | Cytotoxic saponins from the Chinese herbal drug Yunnan Bai Yao | |
| WO2005095438A1 (en) | Saponins, the preparation and the use of the same | |
| JPS6352013B2 (en) | ||
| JP4020992B2 (en) | A new saponin glycoside derived from Ginseng | |
| CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
| JP3998282B2 (en) | A new saponin glycoside derived from Ginseng | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN114057764B (en) | Linderane type dimeric sesquiterpene with anti-inflammatory activity and preparation method and application thereof | |
| CN108096318B (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof | |
| Lee et al. | Identification of dammarane-type triterpenoid saponins from the root of Panax ginseng | |
| CN111454317B (en) | Panaxadiol type triterpenoid saponin, folium Notoginseng extract, pharmaceutical composition and cosmetic composition with antiinflammatory activity | |
| CN110922444B (en) | Panaxadiol type triterpenoid saponin with anti-inflammatory activity | |
| Lacaille-Dubois | Biologically and pharmacologically active saponins from plants: recent advances | |
| US10874705B2 (en) | Extracts and isolated compounds from cakile arabica for treatment of ulcer | |
| CN110680819A (en) | Application of triterpenoid saponin compound | |
| JPS625126B2 (en) | ||
| KR0179415B1 (en) | Novel saponin component and purification thereof | |
| CN1095669C (en) | Medicine composition of saponin containing protopanaxyndiol component and preparing process and application thereof | |
| CN102351874B (en) | New erigeroster compound with medicinal activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070417 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070710 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070807 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |